RMIT University
Browse

Antibody–Biopolymer Conjugates in Oncology: A Review

Download (816.12 kB)
journal contribution
posted on 2025-10-29, 23:38 authored by Vivek P Chavda, Pankti C Balar, Divya Teli, Majid Davidson, Joanna Bojarska, Vasso ApostolopoulosVasso Apostolopoulos
Cancer is one of the most prevalent diseases and affects a large proportion of the population worldwide. Conventional treatments in the management include chemotherapy, radiotherapy, and surgery. Although being well-accepted, they have many lacunas in the form of severe side effect resulting from lack of targeted delivery. Antibody biopolymer conjugates are a novel method which is an add-on to older methods of immunization. It is used in various diseases and disorders. It ensures the targeted delivery of molecules to increase its efficacy and reduce unwanted effects of the molecule/drug to normal cells. It shows miraculous results in the treatment and management of several cancers even in advanced stages. Herein, we present the chemistry between biopolymer and antibody, their effects on cancer as well as the basic differences between antibody-drug conjugates and antibody-biopolymer conjugates.<p></p>

History

Related Materials

  1. 1.
  2. 2.
  3. 3.
    PMID - Has metadata PubMed 36985578
  4. 4.
    PMID - Has metadata PubMed PMC10053780
  5. 5.
    DOI - Is published in DOI: 10.3390/molecules28062605
  6. 6.
    ISSN - Is published in 1431-5157 (Molecules)
  7. 7.
    EISSN - Is published in 1420-3049 (Molecules)

Journal

Molecules

Volume

28

Issue

6

Total pages

9

Publisher

MDPI

Language

eng

Copyright

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Open access

  • Yes

Usage metrics

    Scholarly Works

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC